TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Effect on blood lipids as measured by serum Levels of Cholesterol, triglycerides, cholesterol metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants With adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of maximum tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: Change in patient-rated pain on load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants correctly diagnosed with VL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants treated for VL and identified as cured (ToC) at day 17 post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood chemistry to assess for liver de-compensation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Tolerability of the ketogenic diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: aesthetic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Post-Concussion Symptoms Scale (PCSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Differences in analyte values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Signal coherence and EEG power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: median change from baseline values in gastric acid secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum Silver Concentration at 1 Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Silver Concentration at 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Silver Concentrate at 28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Binge Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite and individual components of cardiovascular death, MI, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Bleeding rates within 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy measured by the Mayo Clinic modified endoscopic subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receiver operator characteristic curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anxiety and Depression assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in lumbar pain interferences
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Muscular Imbalances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postural Dysfunctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Drug accountability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Toxicity reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Coughing Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in physician communication behaviors
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Glycemic Control in pre-pregnant group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glycemic Control in pregnant group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety and tolerability of MLN1202
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of MLN1202
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-Hour Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Passed Bladder Trial
Endpoint domain: Mortality/survival
Primary endpoint: Cmax for Carbidopa and Levodopa Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for Levodopa and Carbidopa Plasma Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve for Levodopa and Carbidopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean central subfield thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Percentage of Subjects Reporting Any Adverse Events of Interest (AEIs) and/or Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Percentage of Subjects Reporting Gastrointestinal Disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Percentage of Subjects Reporting Immune System Disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of culture-confirmed or clinical neonatal sepsis
Endpoint domain: Mortality/survival
Primary endpoint: Rate of vertical transmission of colonization with group B streptococcus (GBS)
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative three-months incidence of re-operation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of hypophosphatemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Cognitive Performance measure (B-CAM)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Abdominal discomfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Subcutaneous Recombinant Human IL-15
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose-limiting Toxicities (DLTs) of Subcutaneous Recombinant Human IL-15
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events Related to Subcutaneous rhIL-15
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in the Number of Actinic Keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self-perceived psychological wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Weight Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Partial Mayo Clinic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hemoglobin A1c (HbA1c) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in functionality of the elderly
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Ultrasound HEAD-US score of index joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase rate of survival
Endpoint domain: Mortality/survival
Primary endpoint: Decrease incidence of relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease incidence of metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of CD68+ and CD8+ inflammatory cells per area of biopsy tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage and total number of neutrophils in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abnormal Sperm DNA Fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Choroidal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Yale Global Tic Severity Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Device-related NACE
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of stone removal operations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of The Wexner Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Sensitivity of PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic Specificity of PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With CDAI Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipoprotein response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: All cause pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Flanker Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis agreement within the multidisciplinary team discussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measured with EORTC QLQ-C30 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life measured with QLQ-MY20 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Minimal effective dose of tranexamic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infant acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in protein expression of autophagy markers in leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in relative protein expression of inflammatory mediators in leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative vaginal cuff prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 Acute GVHD Rate
Endpoint domain: Adverse events/effects
Primary endpoint: plasma circulating cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Satisfaction with consent decision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understanding of consent content
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fat mass post
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean mass post
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral Fat post
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression free survival at 27 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in Mental Time Travel Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Time Estimation Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Time Reproduction Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Metabolites of cerebrospinal fluid, blood and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second primary cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of perineal skin opening requiring re-closure post-partum
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Wound Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analog scale area under the curve (VAS-AUC) for dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptomatic Improvement by Overall Treatment Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appropriateness of hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improvement in Range of Motion, Flexion, and Extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of Collagen Remodeling (Increased Dermal Echogenicity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in Skin Thickness and Sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Participant's Decisional Conflict Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of Participant's Post Return of Results Decision Regret Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Clearance Following Oral Administration (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of device for diagnosis of ON
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From the Baseline in Total Kidney Volume (TKV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Suicidality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shrinkage of tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in cardiac output at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With at Least 4-fold Rise in rLP2086 Specific Serum Bactericidal Assay Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Atleast One Adverse Event (AE): Stage 1
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Atleast One Adverse Event (AE): Stage 2
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal oxygen saturations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experiencing at Least One Adverse Event (AE) During the Treatment Period and First 14 Follow-up Days
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuing Study Therapy Due to an AE During the Treatment Period and First 14 Follow-up Days
Endpoint domain: Adverse events/effects
Primary endpoint: KAP change from baseline at 6-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: KAP change from baseline at 12-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Skin Laxity in Submental Region and Neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lift in Brow Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Blood Flow Velocity in Middle Cerebral Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oxygen Saturation of Jugular Venous Bulb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anti-tumor effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects With ≥50% Reduction in Average Post-Amputation Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Experienced at Least One Study-Related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Need for intensive care unit admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Packed red blood cells transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Treatment Durability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiographic in-lesion late loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear film break up time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Tear meniscus height (LTMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Tear meniscus area (LTMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central corneal clearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of atorvastatin and its active metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of atorvastatin and its active metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adverse events, clinical lab abnormalities and other safety findings
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Roland- Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of sub-epithelial lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Weight loss of at least 3%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline of episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With Administration-Associated Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Safety profile of REGN1400
Endpoint domain: Adverse events/effects
Primary endpoint: Therapy Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in number of extra ventricular beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of antenatal booking before 20 weeks gestation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of presentation for post-natal care within 7 days of delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of exclusive breast-feeding practice at 14 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coverage of HIV PCR testing at 6 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Early diagnosis of protein losing enteropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Initiators for United Healthcare Patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Initiators for MarketScan Patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Switching for United Healthcare Patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Switching for MarketScan Patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Augmentation for United Healthcare Patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment Augmentation for MarketScan Patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Functional Anti-chikungunya Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Central Aortic Distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ankle-brachial index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ultrasound scan of the operated segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CT-angiography of lower limb arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serum irisin hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnostic efficacy of colorectal cancer model
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intensity of bone pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface of osteolytic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes